1. Report Introduction 2. Lymphangioleiomyomatosis (LAM) 2.1. Lymphangioleiomyomatosis Disease Overview 2.2. Lymphangioleiomyomatosis History 2.3. Lymphangioleiomyomatosis Symptoms 2.4. Lymphangioleiomyomatosis Causes 2.5. Lymphangioleiomyomatosis Pathophysiology 2.6. Lymphangioleiomyomatosis Diagnosis 2.6.1. Diagnostic Guidelines 3. Lymphangioleiomyomatosis Current Treatment Patterns 3.1. Treatment Guidelines 4. Lymphangioleiomyomatosis - DelveInsight’s Analytical Perspective 4.1. In-depth Commercial Assessment 4.1.1. Lymphangioleiomyomatosis companies collaborations, Licensing, Acquisition –Deal Value Trends 4.1.1.1. Assessment Summary 4.1.2. Lymphangioleiomyomatosis Collaboration Deals 4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis 4.1.2.2. Lymphangioleiomyomatosis Acquisition Analysis 4.2. Clinical Assessment of Pipeline Drugs 4.2.1. Assessment by Phase of Development 4.2.2. Assessment by Product Type (Mono / Combination) 4.2.2.1. Assessment by Stage and Product Type 4.2.3. Assessment by Route of Administration 4.2.3.1. Assessment by Stage and Route of Administration 4.2.4. Assessment by Molecule Type 4.2.4.1. Assessment by Stage and Molecule Type 4.2.5. Assessment by MOA 4.2.5.1. Assessment by Stage and MOA 5. Lymphangioleiomyomatosis Pipeline Therapeutics 5.1. Late Stage Products (Phase-III) 5.1.1. Comparative Analysis 5.2. Mid Stage Products (Phase-II) 5.2.1. Comparative Analysis 5.3. Early Stage Products (Phase-I) 5.3.1. Comparative Analysis 5.4. Pre-clinical and Discovery Stage Products 5.4.1. Comparative Analysis 5.5. Inactive Products 6. Lymphangioleiomyomatosis -Products Analysis 6.1. Product Profiles 6.1.1. Saracatinib: AstraZeneca 6.1.1.1. Product Description 6.1.1.1.1. Product Overview 6.1.1.1.2. Mechanism of Action 6.1.1.2. Research and Development 6.1.1.2.1. Clinical Studies 6.1.1.2.1.1. Detailed Study Description 6.1.1.2.1.2. Study Results 6.1.1.2.1.3. Clinical Trials: Tabular View 6.1.1.3. Product Development Activities 6.1.1.3.1. Tabulated Product Summary 6.1.1.3.1.1. General Description Table 6.1.2. LAM-001: AI Therapeutics 6.1.2.1. Product Description 6.1.2.1.1. Product Overview 6.1.2.1.2. Mechanism of Action 6.1.2.2. Research and Development 6.1.2.2.1. Clinical Studies 6.1.2.2.1.1. Detailed Study Description 6.1.2.2.1.2. Study Results 6.1.2.2.1.3. Clinical Trials: Tabular View 6.1.2.3. Product Development Activities 6.1.2.3.1. Tabulated Product Summary 6.1.2.3.1.1. General Description Table To be continued in the report………………………… 7. Recent Technologies 8. Lymphangioleiomyomatosis Key Companies 8.1. AI Therapeutics (formerly LAM Therapeutics) 8.2. Boehringer Ingelheim 8.3. AstraZeneca 8.4. Merck Sharp & Dohme 9. Lymphangioleiomyomatosis Key Products 9.1. LAM 001 9.2. Nintedanib 9.3. Saracatinib 9.4. Simvastatin 10. Dormant and Discontinued Products 10.1. Dormant Products 10.1.1. Reasons for being dormant 10.2. Discontinued Products 10.2.1. Reasons for the discontinuation 11. Lymphangioleiomyomatosis - Unmet Needs 12. Lymphangioleiomyomatosis - Future Perspectives 13. Appendix 14. Report Methodology 14.1. Secondary Research 14.2. Expert Panel Validation

Table 1. Diagnostic Guidelines Table 2. Treatment Guidelines Table 3. Assessment Summary Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis Table 5. Lymphangioleiomyomatosis Acquisition Analysis Table 6. Assessment by Phase of Development Table 7. Assessment by Product Type (Mono / Combination) Table 8. Assessment by Stage and Product Type Table 9. Assessment by Route of Administration Table 10. Assessment by Stage and Route of Administration Table 11. Assessment by Molecule Type Table 12. Assessment by Stage and Molecule Type Table 13. Assessment by MOA Table 14. Assessment by Stage and MOA Table 15. Late Stage Products (Phase-III) Table 16. Mid Stage Products (Phase-II) Table 17. Early Stage Products (Phase-I) Table 18. Pre-clinical and Discovery Stage Products Table 19. Inactive Products Table 20. Dormant Products Table 21. Discontinued Products Figure 1. Disease Overview Figure 2. History Figure 3. Symptoms Figure 4. Causes Figure 5. Pathophysiology Figure 6. Diagnostic Guidelines Figure 7. Treatment Guidelines Figure 8. Lymphangioleiomyomatosis companies collaborations, Licensing, Acquisition –Deal Value Trends Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis Figure 10. Lymphangioleiomyomatosis Acquisition Analysis Figure 11. Assessment by Phase of Development Figure 12. Assessment by Product Type (Mono / Combination) Figure 13. Assessment by Stage and Product Type Figure 14. Assessment by Route of Administration Figure 15. Assessment by Stage and Route of Administration Figure 16. Assessment by Molecule Type Figure 17. Assessment by Stage and Molecule Type Figure 18. Assessment by MOA Figure 19. Assessment by Stage and MOA Figure 20. Late Stage Products (Phase-III) Figure 21. Mid Stage Products (Phase-II) Figure 22. Early Stage Products (Phase-I) Figure 23. Pre-clinical and Discovery Stage Products Figure 24. Inactive Products Figure 25. Dormant Products Figure 26. Discontinued Products Figure 27. Unmet Needs

LAM Therapeutics Novartis Boehringer Ingelheim Pfizer AstraZeneca Abbott Merck Sharp & Dohme Hanmi Pharmaceutical mondoBIOTECH Navitor Pharmaceuticals Recursion Pharmaceuticals Merck Sharp & Dohme Genentech